Systemic therapy of advanced hepatocellular carcinoma.

R Galle, Peter; Dufour, Jean-François; Peck-Radosavljevic, Markus; Trojan, Jörg; Vogel, Arndt (2021). Systemic therapy of advanced hepatocellular carcinoma. Future oncology, 17(10), pp. 1237-1251. Future Medicine Ltd. 10.2217/fon-2020-0758

Preview

Text fon-2020-0758.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (2MB) | Preview

For a decade, sorafenib remained the only approved first-line treatment and standard of care for advanced hepatocellular carcinoma. The treatment landscape has been evolving rapidly over the past 2 years with the approval of additional first-and second-line systemic treatments, most of which are targeted therapies. The expected approval of immunotherapies constitutes a paradigm shift: for the first time in years, a checkpoint inhibitor in combination with a VEGF antibody recently outperformed sorafenib with regards to efficacy. The wider availability of systemic therapies increases the chance for longer overall survival but raises new questions concerning the role of local options, treatment choice and sequential treatment. Following an expert discussion at the German Cancer Congress 2020 in Berlin, this article aims to summarize the current evidence on and experience of treatment choice and sequence in first- and second-line therapy.

Interest & Impact

Downloads

244 since deposited on 18 Dec 2020
66 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item